Firm at a glance
Columna Capital is a platform private equity firm founded in 2009 and headquartered in London, with an additional office in Luxembourg [S1].
What they buy
Columna Capital’s portfolio demonstrates a focus on European healthcare, animal health, agri-food, and insurance and business services companies [S2]. The firm appears to pursue platform investments that can be expanded through add-on acquisitions, as evidenced by multiple bolt-on transactions supporting existing portfolio companies [S3]. Approximately €1 billion in assets under management supports this buy-and-build strategy, with Fund III closing at over €300 million in June 2024 [S1][S4].
Portfolio
Healthcare
Physidia (platform, acquired May 2023), Over (platform, acquired August 2022), Ardentis (platform), and Bianalisi (platform) [S2].
Animal Health
Santévet (platform), MiVet (platform), and Datamars (platform, also agri-food) [S2].
Agri-food
Zumex (platform, acquired October 2023) and Datamars (platform, also animal health) [S2].
Insurance & Business Services
MSA Mizar Group (platform, acquired March 2022), Santévet (platform, also animal health), and Carter (platform) [S2].
Recent activity (last 24 months)
* May 2026: Acquisition of Evidenze Group [S3]
* March 2026: Physidia acquired Nordic Medcom as an add-on [S3]
* January 2026: Exit of majority stake in MSA Mizar to TowerBrook [S3]
* July 2025: Santévet acquired Tedaisy as an add-on [S3]
* December 2024: MSA Mizar acquired Veta+ as an add-on [S3]
* June 2024: Closed Fund III at over €300 million [S4]
How this firm fits a seller
Columna Capital appears well suited for European mid-market businesses in healthcare, animal health, agri-food, or insurance services sectors seeking a platform investor with demonstrated buy-and-build capabilities [S2][S3]. The firm’s recent exit of MSA Mizar to TowerBrook in January 2026 provides evidence of liquidity events for portfolio companies [S3]. With two add-on acquisitions in the trailing twelve months and a freshly closed fund as of mid-2024, the firm appears positioned to support both organic and inorganic growth strategies [S3][S4]. Sellers in veterinary services, diagnostic healthcare, or specialty insurance may find sector alignment with existing portfolio themes.
Sources
[S1] https://www.columnacapital.com/about-us (as of 2025-01-15)
[S2] https://www.columnacapital.com/investments (as of 2025-01-15)
[S3] https://www.columnacapital.com/media/press-releases (as of 2026-05-05)
[S4] https://www.columnacapital.com/media/press-releases (as of 2024-06-20)
Frequently asked questions
Does Columna Capital buy healthcare businesses?
Yes, healthcare represents a significant portion of Columna Capital’s portfolio per public sources [S2]. The firm has acquired platform companies including Physidia in May 2023, Over in August 2022, and maintains investments in Ardentis and Bianalisi [S2]. Recent add-on activity such as Physidia’s acquisition of Nordic Medcom in March 2026 suggests continued healthcare sector focus [S3].
What companies has Columna Capital acquired recently?
Columna Capital’s most recent platform acquisition was Evidenze Group in May 2026 [S3]. The firm also completed two add-on transactions in the past year: Physidia acquired Nordic Medcom in March 2026, and Santévet acquired Tedaisy in July 2025 [S3].
Where is Columna Capital based and how big is the firm?
Columna Capital is headquartered in London with an additional office in Luxembourg [S1]. The firm reports over €1 billion in assets under management, with its most recent fund (Fund III) closing at over €300 million in June 2024 [S1][S4].
Is Columna Capital still actively acquiring?
Yes, Columna Capital appears actively acquiring based on recent transaction history. The firm completed a platform acquisition of Evidenze Group in May 2026 and two add-on acquisitions in the past twelve months [S3]. The June 2024 close of Fund III further suggests active deployment capacity [S4].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.